Table 3.
Changes in MDSC% during gemcitabine and capecitabine chemotherapy correlated with changes in serum TNFα, MCP-1, IL-1b, IL-6 and VEGF in patients with stable disease on therapy
| Patients | MDSC (%) | TNFα (pg/ml) | MCP-1 (pg/ml) | IL-1b (pg/ml) | IL-6 (pg/ml) | VEGF (pg/ml) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| 1 | 2.58 | 18.16 | 36.24 | 30.02 | 5.19 | 10.04 | 2.82 | 2.37 | 11.13 | 266.67 | 79.08 | 45.66 |
| 2 | 0.75 | 1.41 | 34.27 | 13.87 | 17.45 | 6.22 | 2.27 | 1.13 | 9.11 | 4.40 | 148.52 | 38.89 |
| 3 | 2.25 | 3.33 | 69.34 | 69.93 | 23.21 | 17.00 | 3.06 | 2.51 | 24.29 | 87.04 | 37.53 | 70.69 |
| 4 | 0.62 | 0.8 | 135.53 | 74.27 | 33.57 | 30.69 | 6.31 | 4.69 | 20.65 | 19.39 | 97.05 | 60.86 |
| 5 | 1.00 | 1.25 | 47.07 | 67.00 | 42.59 | 47.1 | 2.99 | 3.51 | 11.67 | 18.19 | 100.04 | 376.92 |
| 6 | 1.86 | 2.02 | 71.8 | 60.48 | 69.62 | 58.53 | 4.22 | 4.54 | 22.47 | 18.73 | 82.76 | 29.18 |
| 7 | 1.06 | 0.82 | 54.65 | 53.69 | 26.08 | 30.45 | 3.62 | 3.71 | 12.98 | 11.74 | 6.87 | 3.05 |
| 8 | 2.54 | 1.59 | 192.74 | 25.14 | 266.73 | 17.35 | 10.62 | 1.68 | 152.72 | 8.66 | 213.81 | 10.26 |
| 9 | 2.00 | 1.08 | 68.17 | 40.02 | 71.78 | 68.12 | 3.16 | 1.73 | 12.83 | 9.86 | 225.10 | 51.15 |
| 10 | 1.84 | 0.59 | 78.58 | 72.61 | 30.67 | 44.86 | 6.08 | 7.77 | 54.33 | 36.62 | 108.04 | 29.81 |
PBMC from ten patients with stable disease during gemcitabine and capecitabine treatment were analyzed both pre- and post-treatment by flow cytometry for changes in Lin-DR-CD11b+ cells and changes in serum cytokines TNFα, MCP-1, IL-1b, IL-6 and VEGF by the Bio Rad Bio Plex 27 Pro Cytokine, Chemokine and Growth Factor assay